Evidence map›Paper›PMID 42387344›Full record

ArticleJournal of clinical laboratory analysis2026

Investigation of Specific IgG-Secreting Cells in Congenital Toxoplasmosis: The TOXODIAG Study.

F Migot-Nabias, N Beldjoudi, K Bailly, M Andrieu, M Surenaud, K Gbedande, C Couffignal, L Mandelbrot, H Yera, S Houzé and 2 more

Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03385499 (TOXODIAG), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03385499 nacompletednot on this map

TOXODIAG: New Diagnostic Approach for Congenital Toxoplasmosis

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2018 to 2024Enrolled70ConditionsCongenital ToxoplasmosisArmsblood additional samples
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

F Migot-NabiasUniversité Paris Cité, IRD, Inserm, MERIT, Paris, France.ORCID https://orcid.org/0000-0001-9982-594X
N BeldjoudiDépartement d'épidémiologie et de recherche clinique, AP-HP, GH Paris Nord Val de Seine, Paris, France.
K BaillyUniversité Paris Cité, Inserm, CNRS, Plateforme CYBIO, Institut Cochin, Paris, France.
M AndrieuUniversité Paris Cité, Inserm, CNRS, Plateforme CYBIO, Institut Cochin, Paris, France.
M SurenaudInserm U955, Institut Mondor de Recherche Biomédicale, Créteil, France.
K GbedandeCentre d'Etude et de Recherche sur les Pathologies Associées à la Grossesse et à l'Enfance (CERPAGE), Faculté des Sciences de la Santé, Cotonou, Bénin.
C CouffignalDépartement d'épidémiologie et de recherche clinique, AP-HP, GH Paris Nord Val de Seine, Paris, France.ORCID https://orcid.org/0000-0002-5006-6249
L MandelbrotService de Gynécologie-Obstétrique, AP-HP, Hôpital Louis Mourier, Colombes, France.ORCID https://orcid.org/0000-0002-5883-7597
H YeraLaboratoire de Parasitologie-Mycologie, AP-HP, Hôpital Cochin, Paris, France.
S HouzéUniversité Paris Cité, IRD, Inserm, MERIT, Paris, France.
M DambrunUniversité Paris Cité, IRD, Inserm, MERIT, Paris, France.ORCID https://orcid.org/0000-0001-7391-6800
TOXODIAG Study Group

Funding

Assistance Publique - Hôpitaux de Paris
6 · The paper itself

Abstract

backgroundCurrent neonatal diagnostic tests for congenital toxoplasmosis (CT) have limited performance, which is particularly problematic in resource-limited settings and where monitoring for toxoplasmosis during pregnancy is lacking. The TOXODIAG study (NCT03385499) aimed to detect specific IgGs as soon as they appear in pregnant women with acute infection with Toxoplasma gondii (Tg) and their newborns suspected of infection.

methodsSeventy pregnant women were included in five perinatal centers in Paris, France. They were divided into three groups based on their Toxoplasma seroconversion during pregnancy (n = 20, group of interest) and their immune status at delivery with latent infection (n = 23) or confirmed absence of infection (n = 27, control groups). The enzyme-linked immunospot (ELISPOT) method was used to detect B lymphocytes primed to produce IgG against the recombinant antigens TgSAG1, TgGRA7, and TgAMA1.

resultsComplete and validated ELISPOT results were obtained for 9 women in the SEROCO group, including 1 of the 5 CT cases resulting from pregnancy in this group. Tg-specific IgG-secreting cells were observed in mothers at the time of diagnosis of Tg seroconversion and delivery, but not in cord blood. A simplified version of the ELISPOT test, combining the three Tg antigens in a single plate well, reproduced the information provided by the antigens considered independently, with a positivity rate of 35% compared to a range of 6%-37%.

conclusionThe ELISPOT method could be useful for maternal screening, but for postnatal detection of Tg-specific IgG-secreting cells, it either requires further technical improvements or is not a suitable method.

Indexed as

Antibodies, ProtozoanImmunoglobulin GToxoplasmosis, CongenitalAdultEnzyme-Linked Immunospot AssayFemaleHumansInfant, NewbornPregnancyPregnancy Complications, ParasiticToxoplasmaAntibodies, ProtozoanImmunoglobulin Gantibody secreting cellB lymphocytecongenital infectionELISPOTimmunoglobulin Gnewbornpregnancyseroconversiontoxoplasmosis

Identifiers

PMID42387344
PMCPMC13399916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.